| 中文名稱:化合物 ASP 3026 | 英文名稱:ASP3026 |
| CAS:1097917-15-1 | 品牌: TargetMol |
| 產(chǎn)地: 美國 | 保存條件: Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 純度規(guī)格: 99.34% | 產(chǎn)品類別: 抑制劑 |
| 貨號: T001|T1962 |
| 名稱 | ASP3026 |
| 描述 | ASP3026 has been used in trials studying the treatment of Solid Tumor, B-Cell Lymphoma, Advanced Malignancies, Positive for Anaplastic Lymphoma Kinase, and Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS. |
| 激酶實驗 | Recombinant truncated FLAG-tagged mTOR expressed in HEK 293 cells is used in biochemical assays, together with a biotinylated p70S6K peptide substrate. Streptavidin donor and protein A acceptor beads are used to assemble the capture complex for generation of the assay signal. The activity of the lipid kinases, PI3K alpha, beta, delta, and gamma are measured using recombinant proteins and the lipid PIP2 as substrate. Assays for ATM and DNA-PK activity are performed. The mTOR cellular activity is measured in MDAMB468 cells, using an Acumen laser scanning cytometer to analyze the levels of phosphorylation of S6 (Ser235/236) and AKT (Ser473)[1]. |
| 體外活性 | 以每天兩次口服給藥ASP3026的方式處理荷有皮下NCI-H2228腫瘤異種移植物的小鼠14天,誘導(dǎo)劑量依賴性的抗腫瘤作用,從1 mg/kg開始,在10,30和100 mg/kg強烈消退. |
| 體內(nèi)活性 | ASP3026抑制內(nèi)源性表達EML4-ALK變體3的人NSCLC腫瘤細胞系NCI-H2228的生長,IC50值為64.8 nM。ASP3026在酪氨酸激酶中比PF02341066顯示更強的選擇性抑制ALK活性。 |
| 存儲條件 | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (3.44 mM), Sonication is recommended. 10% DMSO+90% Saline : 1.04 mg/mL (1.79 mM), Solution. DMSO : 10.42 mg/mL (17.94 mM), Sonication is recommended. |
| 關(guān)鍵字 | Inhibitor | inhibit | Cluster of differentiation 246 | CD246 | ASP-3026 | ASP3026 | Apoptosis | Anaplastic lymphoma kinase (ALK) | Anaplastic lymphoma kinase | ALK tyrosine kinase receptor | ALK |
| 相關(guān)產(chǎn)品 | Formamide | Urea | Dimethyl phthalate | Aceglutamide | Alginic acid | Cysteamine hydrochloride | Metronidazole | Sildenafil citrate | Citric Acid Triammonium | Stavudine | Tamoxifen | Ethyl linoleate |
| 相關(guān)庫 | 抑制劑庫 | 經(jīng)典已知活性庫 | 抗癌活性化合物庫 | 已知活性化合物庫 | 激酶抑制劑庫 | 細胞骨架化合物庫 | 膜蛋白靶向化合物庫 | 免疫/炎癥分子化合物庫 | 藥物功能重定位化合物庫 | 酪氨酸激酶分子庫 | 抗癌臨床化合物庫 | 抗癌藥物庫 |
| 成立日期 | 2013-04-18 (14年) | 注冊資本 | 566.265100萬人民幣 |
| 員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
| 主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
| 產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
|---|---|---|---|---|
| 詢價 |
VIP7年
|
上海澤葉生物科技有限公司
|
2026-06-09 | |
| ¥146.90 |
VIP14年
|
上海阿拉丁生化科技股份有限公司
|
2026-05-14 | |
| ¥146.90 |
VIP3年
|
上海阿拉丁生化科技股份有限公司
|
2025-05-16 | |
| 詢價 |
南京百鑫德諾生物科技有限公司
|
2024-09-26 | ||
| 詢價 |
珠海市活力達生物科技有限公司
|
2015-04-29 |